ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

KYMR Kymera Therapeutics Inc

36.51
0.21 (0.58%)
最終更新日: 23:28:23
15分遅延
名称 銘柄コード 市場 種別
Kymera Therapeutics Inc KYMR NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
0.21 0.58% 36.51 23:28:23
始値 安値 高値 終値 前日終値
37.35 36.51 38.21 36.30
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/5/0220:00GLOBEKymera Therapeutics Announces First Quarter 2024 Financial..
2024/4/2520:00GLOBEKymera Therapeutics to Report First Quarter 2024 Financial..
2024/4/0820:00GLOBEKymera Therapeutics Announces Scientific Presentations at..
2024/3/0900:00GLOBEKymera Therapeutics Presents Preclinical Data for STAT6 and..
2024/3/0508:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0508:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0508:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0507:50EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0507:47EDGAR2Form 144 - Report of proposed sale of securities
2024/2/2821:00GLOBEKymera Therapeutics to Participate in Upcoming March..
2024/2/2806:22EDGAR2Form 144 - Report of proposed sale of securities
2024/2/2221:32EDGAR2Form S-8 - Securities to be offered to employees in employee..
2024/2/2221:10EDGAR2Form 8-K - Current report
2024/2/2221:00GLOBEKymera Therapeutics Announces Fourth Quarter and Full Year..
2024/2/1521:00GLOBEKymera Therapeutics to Report Fourth Quarter and Full Year..
2024/2/1009:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/1006:22EDGAR2Form 144 - Report of proposed sale of securities
2024/1/3121:00GLOBEKymera Therapeutics to Present in Fireside Chat at the..
2024/1/0923:17GLOBEKymera Therapeutics Outlines Key 2024 Objectives and..
2024/1/0923:15GLOBEKymera Therapeutics Announces Closing of Upsized $275..
2024/1/0606:11EDGAR2Form 8-K - Current report
2024/1/0606:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/1/0520:00GLOBEKymera Therapeutics Announces Pricing of $275 Million Public..
2024/1/0506:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/1/0506:01GLOBEKymera Therapeutics Announces Proposed Public Offering
2024/1/0421:08EDGAR2Form 8-K - Current report
2024/1/0421:00GLOBER&D Day Highlights Kymera’s Immunology Strategy and Emerging..
2024/1/0307:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0221:00GLOBEKymera Therapeutics to Present at the 42nd Annual J.P...
2023/12/1321:00GLOBEKymera Therapeutics to Host Virtual Immunology R&D Day on..
2023/12/1111:00GLOBEKymera Therapeutics Presents Interim Results from STAT3..
2023/12/0721:00GLOBEKymera Therapeutics Announces First Patient Dosed in Phase 2..
2023/11/1401:00GLOBEKymera Therapeutics Announces Publication of Phase 1 Trial..
2023/11/0708:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/0222:15EDGAR2Form 8-K - Current report
2023/11/0222:00GLOBEKymera Therapeutics to Present New Clinical Data from the..
2023/11/0220:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0220:10EDGAR2Form 8-K - Current report
2023/11/0220:00GLOBEKymera Therapeutics Announces Third Quarter 2023 Financial..
2023/11/0120:00GLOBEKymera Therapeutics to Participate in Upcoming November..
2023/10/2720:00GLOBEKymera Therapeutics Announces First Patient Dosed in Phase 2..
2023/10/2620:00GLOBEKymera Therapeutics to Report Third Quarter 2023 Financial..
2023/10/1620:00GLOBEKymera Therapeutics Presents Preclinical Data Demonstrating..
2023/9/1820:00GLOBEKymera Therapeutics Receives U.S. FDA Fast Track Designation..
2023/8/0905:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/8/0320:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/0320:10EDGAR2Form 8-K - Current report
2023/8/0320:00GLOBEKymera Therapeutics Announces Second Quarter 2023 Financial..
2023/7/2720:00GLOBEKymera Therapeutics to Report Second Quarter 2023 Financial..
2023/6/2222:21DJNKymera Therapeutics Gets Orphan-Drug Status for Leukemia..

最近閲覧した銘柄

Delayed Upgrade Clock